BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 31587797)

  • 1. Aspirin sensitivity: Lessons in the regulation (and dysregulation) of mast cell function.
    Boyce JA
    J Allergy Clin Immunol; 2019 Oct; 144(4):875-881. PubMed ID: 31587797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COX-1 mediates IL-33-induced extracellular signal-regulated kinase activation in mast cells: Implications for aspirin sensitivity.
    Pan D; Buchheit KM; Samuchiwal SK; Liu T; Cirka H; Raff H; Boyce JA
    J Allergy Clin Immunol; 2019 Mar; 143(3):1047-1057.e8. PubMed ID: 30017554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aspirin-Exacerbated Respiratory Disease Involves a Cysteinyl Leukotriene-Driven IL-33-Mediated Mast Cell Activation Pathway.
    Liu T; Kanaoka Y; Barrett NA; Feng C; Garofalo D; Lai J; Buchheit K; Bhattacharya N; Laidlaw TM; Katz HR; Boyce JA
    J Immunol; 2015 Oct; 195(8):3537-45. PubMed ID: 26342029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thymic stromal lymphopoietin controls prostaglandin D2 generation in patients with aspirin-exacerbated respiratory disease.
    Buchheit KM; Cahill KN; Katz HR; Murphy KC; Feng C; Lee-Sarwar K; Lai J; Bhattacharyya N; Israel E; Boyce JA; Laidlaw TM
    J Allergy Clin Immunol; 2016 May; 137(5):1566-1576.e5. PubMed ID: 26691435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aspirin activation of eosinophils and mast cells: implications in the pathogenesis of aspirin-exacerbated respiratory disease.
    Steinke JW; Negri J; Liu L; Payne SC; Borish L
    J Immunol; 2014 Jul; 193(1):41-7. PubMed ID: 24890720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aspirin-exacerbated respiratory disease.
    Wangberg H; White AA
    Curr Opin Immunol; 2020 Oct; 66():9-13. PubMed ID: 32299015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of group 2 innate lymphocytes in aspirin-exacerbated respiratory disease pathogenesis.
    White AA; Doherty TA
    Am J Rhinol Allergy; 2018 Jan; 32(1):7-11. PubMed ID: 29336282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PGE suppresses excessive anti-IgE induced cysteinyl leucotrienes production in mast cells of patients with aspirin exacerbated respiratory disease.
    Wang XS; Wu AY; Leung PS; Lau HY
    Allergy; 2007 Jun; 62(6):620-7. PubMed ID: 17508965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostaglandin E2 deficiency causes a phenotype of aspirin sensitivity that depends on platelets and cysteinyl leukotrienes.
    Liu T; Laidlaw TM; Katz HR; Boyce JA
    Proc Natl Acad Sci U S A; 2013 Oct; 110(42):16987-92. PubMed ID: 24085850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostaglandin E2 in NSAID-exacerbated respiratory disease: protection against cysteinyl leukotrienes and group 2 innate lymphoid cells.
    Rusznak M; Peebles RS
    Curr Opin Allergy Clin Immunol; 2019 Feb; 19(1):38-45. PubMed ID: 30516547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Advances in aspirin-exacerbated respiratory disease (AERD)].
    Higashi N; Mitsui C; Taniguchi M
    Nihon Rinsho; 2016 Oct; 74(10):1683-1687. PubMed ID: 30551280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aspirin-exacerbated respiratory disease (AERD): Current understanding of AERD.
    Taniguchi M; Mitsui C; Hayashi H; Ono E; Kajiwara K; Mita H; Watai K; Kamide Y; Fukutomi Y; Sekiya K; Higashi N
    Allergol Int; 2019 Jul; 68(3):289-295. PubMed ID: 31235242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Updates on immune mechanisms in aspirin-exacerbated respiratory disease.
    Laidlaw TM; Boyce JA
    J Allergy Clin Immunol; 2023 Feb; 151(2):301-309. PubMed ID: 36184313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular interactions in aspirin-exacerbated respiratory disease.
    Badrani JH; Doherty TA
    Curr Opin Allergy Clin Immunol; 2021 Feb; 21(1):65-70. PubMed ID: 33306487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on Aspirin-Exacerbated Respiratory Disease.
    Woessner KM
    Curr Allergy Asthma Rep; 2017 Jan; 17(1):2. PubMed ID: 28097500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induced sputum eicosanoids during aspirin bronchial challenge of asthmatic patients with aspirin hypersensitivity.
    Mastalerz L; Celejewska-Wójcik N; Wójcik K; Gielicz A; Januszek R; Cholewa A; Stręk P; Sanak M
    Allergy; 2014 Nov; 69(11):1550-9. PubMed ID: 25123806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Group 2 innate lymphoid cells are recruited to the nasal mucosa in patients with aspirin-exacerbated respiratory disease.
    Eastman JJ; Cavagnero KJ; Deconde AS; Kim AS; Karta MR; Broide DH; Zuraw BL; White AA; Christiansen SC; Doherty TA
    J Allergy Clin Immunol; 2017 Jul; 140(1):101-108.e3. PubMed ID: 28279492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eosinophil production of prostaglandin D
    Feng X; Ramsden MK; Negri J; Baker MG; Payne SC; Borish L; Steinke JW
    J Allergy Clin Immunol; 2016 Oct; 138(4):1089-1097.e3. PubMed ID: 27423494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aspirin or other nonsteroidal inflammatory agent exacerbated asthma.
    Ledford DK; Wenzel SE; Lockey RF
    J Allergy Clin Immunol Pract; 2014; 2(6):653-7. PubMed ID: 25439353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of Mast Cells in Aspirin-Exacerbated Respiratory Disease (AERD) Pathogenesis: Implications for Future Therapeutics.
    Kuruvilla ME; Vanijcharoenkarn K; Levy JM
    J Asthma Allergy; 2020; 13():463-470. PubMed ID: 33116654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.